Zealand Pharma and Roche Release Phase 2 Topline Data for Amylin Analogue Petrelintide
Zealand Pharma (ZLDPF) announced topline results from its phase 2 ZUPREME-2 trial of the amylin analogue petrelintide. The drug demonstrated significant weight reduction and improvement in A1C levels compared to a placebo, according to preliminary data. The study involved 220 participants who are overweight or obese. These findings suggest potential for further development as a treatment option for metabolic disorders such as diabetes and obesity. Zealand is collaborating with Roche on the trial, which could influence future investment in the drug's pipeline.
Topics: Diabetes Treatment Pharmaceuticals Weight Loss Drugs